Diabetes and hepatitis C: A two-way association

Sara Salehi Hammerstad, Shira Frankel Grock, Hanna J. Lee, Alia Hasham, Nina Sundaram, Yaron Tomer

Research output: Contribution to journalReview article

30 Citations (Scopus)

Abstract

Diabetes and hepatitis C infection are both prevalent diseases worldwide, and are associated with increased morbidity and mortality. Most studies, but not all, have shown that patients with chronic hepatitis C are more prone to develop type 2 diabetes (T2D) compared to healthy controls, as well as when compared to patients with other liver diseases, including hepatitis B. Furthermore, epidemiological studies have revealed that patients with T2D may also be at higher risk for worse outcomes of their hepatitis C infection, including reduced rate of sustained virological response, progression to fibrosis and cirrhosis, and higher risk for development of hepatocellular carcinoma. Moreover, hepatitis C infection and mainly its treatment, interferon α, can trigger the development of type 1 diabetes. In this review, we discuss the existing data on this two-way association between diabetes and hepatitis C infection with emphasis on possible mechanisms. It remains to be determined whether the new curative therapies for chronic hepatitis C will improve outcomes in diabetic hepatitis C patients, and conversely whether treatment with Metformin will reduce complications from hepatitis C virus infection. We propose an algorithm for diabetes screening and follow-up in hepatitis C patients.

Original languageEnglish (US)
Article number134
JournalFrontiers in Endocrinology
Volume6
DOIs
StatePublished - Sep 14 2015
Externally publishedYes

Fingerprint

Hepatitis C
Chronic Hepatitis C
Infection
Type 2 Diabetes Mellitus
Fibrosis
Metformin
Virus Diseases
Hepatitis B
Type 1 Diabetes Mellitus
Hepacivirus
Interferons
Liver Diseases
Epidemiologic Studies
Hepatocellular Carcinoma
Therapeutics
Morbidity
Mortality

Keywords

  • Hepatitis C
  • Hepatitis C virus
  • Hepatocellular carcinoma
  • Insulin resistance
  • Interferon alpha
  • Outcomes
  • Treatment
  • Type 1 diabetes
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Hammerstad, S. S., Grock, S. F., Lee, H. J., Hasham, A., Sundaram, N., & Tomer, Y. (2015). Diabetes and hepatitis C: A two-way association. Frontiers in Endocrinology, 6, [134]. https://doi.org/10.3389/fendo.2015.00134

Diabetes and hepatitis C : A two-way association. / Hammerstad, Sara Salehi; Grock, Shira Frankel; Lee, Hanna J.; Hasham, Alia; Sundaram, Nina; Tomer, Yaron.

In: Frontiers in Endocrinology, Vol. 6, 134, 14.09.2015.

Research output: Contribution to journalReview article

Hammerstad, SS, Grock, SF, Lee, HJ, Hasham, A, Sundaram, N & Tomer, Y 2015, 'Diabetes and hepatitis C: A two-way association', Frontiers in Endocrinology, vol. 6, 134. https://doi.org/10.3389/fendo.2015.00134
Hammerstad, Sara Salehi ; Grock, Shira Frankel ; Lee, Hanna J. ; Hasham, Alia ; Sundaram, Nina ; Tomer, Yaron. / Diabetes and hepatitis C : A two-way association. In: Frontiers in Endocrinology. 2015 ; Vol. 6.
@article{f5c3422ba7004516850ec30ec79c43f1,
title = "Diabetes and hepatitis C: A two-way association",
abstract = "Diabetes and hepatitis C infection are both prevalent diseases worldwide, and are associated with increased morbidity and mortality. Most studies, but not all, have shown that patients with chronic hepatitis C are more prone to develop type 2 diabetes (T2D) compared to healthy controls, as well as when compared to patients with other liver diseases, including hepatitis B. Furthermore, epidemiological studies have revealed that patients with T2D may also be at higher risk for worse outcomes of their hepatitis C infection, including reduced rate of sustained virological response, progression to fibrosis and cirrhosis, and higher risk for development of hepatocellular carcinoma. Moreover, hepatitis C infection and mainly its treatment, interferon α, can trigger the development of type 1 diabetes. In this review, we discuss the existing data on this two-way association between diabetes and hepatitis C infection with emphasis on possible mechanisms. It remains to be determined whether the new curative therapies for chronic hepatitis C will improve outcomes in diabetic hepatitis C patients, and conversely whether treatment with Metformin will reduce complications from hepatitis C virus infection. We propose an algorithm for diabetes screening and follow-up in hepatitis C patients.",
keywords = "Hepatitis C, Hepatitis C virus, Hepatocellular carcinoma, Insulin resistance, Interferon alpha, Outcomes, Treatment, Type 1 diabetes, Type 2 diabetes",
author = "Hammerstad, {Sara Salehi} and Grock, {Shira Frankel} and Lee, {Hanna J.} and Alia Hasham and Nina Sundaram and Yaron Tomer",
year = "2015",
month = "9",
day = "14",
doi = "10.3389/fendo.2015.00134",
language = "English (US)",
volume = "6",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Diabetes and hepatitis C

T2 - A two-way association

AU - Hammerstad, Sara Salehi

AU - Grock, Shira Frankel

AU - Lee, Hanna J.

AU - Hasham, Alia

AU - Sundaram, Nina

AU - Tomer, Yaron

PY - 2015/9/14

Y1 - 2015/9/14

N2 - Diabetes and hepatitis C infection are both prevalent diseases worldwide, and are associated with increased morbidity and mortality. Most studies, but not all, have shown that patients with chronic hepatitis C are more prone to develop type 2 diabetes (T2D) compared to healthy controls, as well as when compared to patients with other liver diseases, including hepatitis B. Furthermore, epidemiological studies have revealed that patients with T2D may also be at higher risk for worse outcomes of their hepatitis C infection, including reduced rate of sustained virological response, progression to fibrosis and cirrhosis, and higher risk for development of hepatocellular carcinoma. Moreover, hepatitis C infection and mainly its treatment, interferon α, can trigger the development of type 1 diabetes. In this review, we discuss the existing data on this two-way association between diabetes and hepatitis C infection with emphasis on possible mechanisms. It remains to be determined whether the new curative therapies for chronic hepatitis C will improve outcomes in diabetic hepatitis C patients, and conversely whether treatment with Metformin will reduce complications from hepatitis C virus infection. We propose an algorithm for diabetes screening and follow-up in hepatitis C patients.

AB - Diabetes and hepatitis C infection are both prevalent diseases worldwide, and are associated with increased morbidity and mortality. Most studies, but not all, have shown that patients with chronic hepatitis C are more prone to develop type 2 diabetes (T2D) compared to healthy controls, as well as when compared to patients with other liver diseases, including hepatitis B. Furthermore, epidemiological studies have revealed that patients with T2D may also be at higher risk for worse outcomes of their hepatitis C infection, including reduced rate of sustained virological response, progression to fibrosis and cirrhosis, and higher risk for development of hepatocellular carcinoma. Moreover, hepatitis C infection and mainly its treatment, interferon α, can trigger the development of type 1 diabetes. In this review, we discuss the existing data on this two-way association between diabetes and hepatitis C infection with emphasis on possible mechanisms. It remains to be determined whether the new curative therapies for chronic hepatitis C will improve outcomes in diabetic hepatitis C patients, and conversely whether treatment with Metformin will reduce complications from hepatitis C virus infection. We propose an algorithm for diabetes screening and follow-up in hepatitis C patients.

KW - Hepatitis C

KW - Hepatitis C virus

KW - Hepatocellular carcinoma

KW - Insulin resistance

KW - Interferon alpha

KW - Outcomes

KW - Treatment

KW - Type 1 diabetes

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85013376979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013376979&partnerID=8YFLogxK

U2 - 10.3389/fendo.2015.00134

DO - 10.3389/fendo.2015.00134

M3 - Review article

AN - SCOPUS:85013376979

VL - 6

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

M1 - 134

ER -